The Leaflet Upgrade: Why AI-Powered ePILs Are the Future of Patient Information
For decades, patient information leaflets have been central to medicines communication. Yet in an increasingly digital healthcare world, patients still rely on long, complex documents.
Electronic Product Information (ePI), combined with carefully governed AI, could make approved medicines information easier to find and understand. But this is more than replacing paper with a screen: it challenges how the industry manages and delivers trusted information.
Why ePI, Why Now?
Momentum towards digital product information is growing, driven by regulation, patient expectations and the need for efficiency.
Four forces are shaping this transition:
- Regulatory evolution: European and other ePI programmes are advancing structured digital information, though requirements and timelines vary.
- Patient expectations: European and other ePI programmes are advancing structured digital information, though requirements and timelines vary.
- Operational efficiency: Digital distribution could ease printing and packaging constraints, though change control and compliance remain essential.
- Accessibility: Good digital design can support assistive technologies, multiple languages and diverse needs.
The strategic prize is not a digital leaflet but a reliable information foundation serving patients, professionals and multiple channels.
From Static Information to Intelligent Access
ePI and AI play different roles: ePI provides the approved source; AI could help people navigate it and explain complex terms.
Imagine a patient asking, “Can I take this with coffee?” An AI interface might find the approved text, explain it plainly and refer them to a healthcare professional where clinical judgement is needed.
Potential capabilities include:
- Natural-language search directing users to relevant approved content.
- Multilingual and accessible interfaces designed for different needs
- Context-aware navigation to relevant sections, without inventing personalised advice.
- Aggregated, privacy-conscious insights into recurring information needs, where lawful.
These are possibilities to test, not benefits to assume.
Trust Must Be Designed In
Generative AI can give inaccurate answers, even when grounded in approved sources. Claims that a system “never hallucinates” or is “100% validated” are not defensible.
Responsible solutions need source grounding, traceability, testing, human oversight and clear limits on what the technology can advise. Privacy demands more than claimed HIPAA alignment: data protection law, security and data minimisation must be addressed.
Digital distribution may be faster, but updates still require regulatory approval and controlled implementation. Speed must not compromise accuracy.
Partnering with Vakils
At Vakils, we see this transition as a chance to connect our strengths in regulated content and artwork workflows with emerging digital capabilities.
That means standards-led content management, audit-ready processes and cross-functional collaboration, with AI use cases tested against real needs. The aim is practical progress, not technology for its own sake.
The future of patient information will not be defined by whether the leaflet becomes digital. It will be defined by whether patients can understand and use trusted medicines information more confidently and safely.
Transform your digital leaflets into clear, interactive patient guides. Email us at info@vakilspremedia.com for more information on AI-powered ePILs.
